MPLT - CIK 0001770069
The table below shows MapLight Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 |
|---|---|---|
| Operating cash flow | -$51.18M | -$25.55M |
| Capital expenditure | $24.00K | - |
| Investing cash flow | $67.01M | $37.50M |
| Dividends paid | - | - |
| Stock buybacks | - | - |
| Financing cash flow | -$6.85M | -$47.00K |
MapLight Therapeutics, Inc. reported operating cash flow of -$138.14M for fiscal year 2025. That is down 75.3% from -$78.81M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.